Trulicity Cost in Nevada 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is the Cash Price of Trulicity in Nevada in 2026?

The manufacturer list price for Trulicity sits at $931 per month in Nevada pharmacies in 2026, mirroring the national average because Eli Lilly sets a single wholesale acquisition cost. Cash-pay patients at retail chains such as Smith's, Walgreens, and CVS locations across Las Vegas, Reno, and Henderson generally see a register price close to that figure before any discount program is applied. GoodRx and similar coupon platforms sometimes bring the price to $850 to $920 at select Nevada ZIP codes, though savings vary by week and pharmacy contract.

That $931 price tag puts Trulicity in the same bracket as other branded GLP-1 receptor agonists. For comparison, semaglutide (Ozempic) carries a list price near $936 per month nationally. Neither product has a generic equivalent as of early 2026, so cash-pay patients have limited substitution options within the branded market.

One practical step before paying cash: call the specific Nevada pharmacy and ask for their "GoodRx" or "discount card" price, then compare it to the Lilly savings card offer described in the section below. The difference can exceed $200 per fill at some chains. The FDA label for Trulicity confirms the approved dosing schedule and injection device specifications.

Does Nevada Medicaid (Nevada Check Up / Medicaid Managed Care) Cover Trulicity?

Nevada Medicaid does not cover Trulicity as of 2026. The state's preferred drug list (PDL) for the Division of Health Care Financing and Policy does not include dulaglutide as a covered outgrowth of the standard formulary. Prior authorization requests for Trulicity through Nevada Medicaid have historically been denied unless a patient has a documented cardiovascular indication supported by very specific clinical criteria, and even then coverage is not guaranteed.

Patients enrolled in Nevada Medicaid managed care plans (SilverSummit, Molina Nevada, or Health Plan of Nevada) should verify coverage directly with their plan, because commercial-like Medicaid managed care contracts can occasionally include drugs the fee-for-service PDL excludes. Still, the baseline expectation should be non-coverage.

For Medicaid patients who need a GLP-1, metformin remains the first-line agent on virtually every state Medicaid PDL. Some Nevada Medicaid plans do cover exenatide (Byetta) or liraglutide (Victoza) under specific tier structures, so a prescribing clinician may be able to justify one of those alternatives. The ADA's 2024 Standards of Care emphasize cardiovascular risk reduction as a reason to prioritize GLP-1 agents, stating that "for patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended." That guidance is available through the American Diabetes Association's clinical standards.

What Did the REWIND Trial Show About Dulaglutide's Clinical Value?

Understanding clinical value matters when justifying the cost to insurers or PAs. REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) enrolled 9,901 adults with type 2 diabetes and either established cardiovascular disease or multiple risk factors, then randomized them to dulaglutide 1.5 mg weekly or placebo over a median follow-up of 5.4 years. The Lancet published the results in 2019 (PMID 31189511).

The primary composite endpoint (non-fatal MI, non-fatal stroke, or cardiovascular death) occurred in 12.0% of the dulaglutide group versus 13.4% in the placebo group, a hazard ratio of 0.88 (95% CI 0.79 to 0.99, P<0.05). That 12% relative risk reduction is the clinical cornerstone insurers and formulary committees use when making coverage decisions for dulaglutide. REWIND also showed a 0.61% mean HbA1c reduction from baseline in the dulaglutide arm at 36 months.

Nevada clinicians writing prior authorization letters for Trulicity frequently cite REWIND to argue medical necessity. Whether that argument succeeds depends on the specific insurer and plan year, but REWIND data give the letter its factual spine.

Which Private Insurance Plans Cover Trulicity in Nevada?

Coverage varies sharply by plan type and formulary tier. Here is a practical breakdown for Nevada residents.

Employer-sponsored plans. Roughly 60% of large employer plans nationally include at least one GLP-1 receptor agonist on formulary, according to 2024 pharmacy benefit manager (PBM) data from IQVIA. Trulicity tends to land on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A Tier 3 co-pay in Nevada typically ranges from $60 to $120 per month after the deductible is met. The FDA's Orange Book confirms there is no AB-rated generic for dulaglutide, which keeps it in the brand tier.

ACA marketplace plans. Nevada's state exchange (Nevada Health Link) offers Silver and Gold plans from Anthem, Prominence Health Plan, and Centene. Most Silver-tier ACA plans do not cover Trulicity without prior authorization, and many specifically exclude GLP-1 agents unless the diagnosis code is type 2 diabetes (E11.x). Obesity alone (E66.x) is rarely sufficient for coverage under ACA Nevada plans in 2026.

Medicare Part D. As of 2026, Medicare Part D plans operating in Nevada are required to include at least one GLP-1 agent on their formulary under the CMS enhanced alternative benefit rules, but that agent may be semaglutide rather than dulaglutide. Patients should use the Medicare Plan Finder at cms.gov to compare which NV-region Part D plans list Trulicity specifically. The maximum out-of-pocket for Medicare Part D enrollees is $2 to 000 in 2026 (Inflation Reduction Act provision), so even Tier 5 specialty pricing becomes more manageable in the back half of the benefit year.

VA and Tricare. Nevada has a significant veteran population given Nellis AFB and the Nevada National Guard. The VA National Formulary includes dulaglutide, so veterans receiving care through the VA Southern Nevada Healthcare System or the Reno VA Medical Center may access Trulicity at VA co-pay rates ($0 to $15 per month for most priority groups).

How Does the Eli Lilly Savings Card Work in Nevada?

The Lilly Cares Foundation Insulin Value Program does not directly apply to Trulicity, but Eli Lilly operates a separate savings program called the Trulicity Savings Card. Commercially insured patients in Nevada who are not on a government-funded plan (Medicaid, Medicare, TRICARE, or VA) may pay as little as $25 per monthly fill for up to 24 months. The program has an annual income cap and is not available to patients whose insurance already covers Trulicity at a comparable cost.

To activate the card: visit LillyDiabetes.com, enter your Nevada insurance information, and download or print the card. Most Nevada retail pharmacies accept it at point of sale. The pharmacist scans the card before processing the commercial claim, and Lilly covers the remainder up to their program cap.

Patients without commercial insurance, including those who are uninsured or on Medicaid, are not eligible for the savings card but may qualify for the Lilly Cares patient assistance program, which can provide Trulicity at no cost if household income is at or below 400% of the federal poverty level. In 2026, that threshold is approximately $58,320 for a single-person household.

Is Compounded Dulaglutide Legal in Nevada?

This is the question Nevada patients ask most often, and the answer requires some precision. Compounded dulaglutide produced by a state-licensed 503A compounding pharmacy is currently accessible in Nevada. A 503A pharmacy compounds drugs on a patient-specific, prescription basis and operates under state pharmacy board oversight (in Nevada, the State Board of Pharmacy at pharmacy.nv.gov). Compounded dulaglutide from these pharmacies is not FDA-approved, and the FDA does not independently verify its potency or sterility, but 503A pharmacies must comply with USP 795 and 797 standards for non-sterile and sterile preparations respectively.

The critical legal distinction: 503B outsourcing facilities (which can compound in bulk without individual prescriptions) are prohibited from compounding drugs that are not on the FDA's drug shortage list. Dulaglutide (Trulicity) has not been on the FDA drug shortage list during 2025 to 2026. This means 503B facilities cannot legally compound dulaglutide in bulk. However, 503A pharmacies compounding for an individual patient based on a valid prescription from a Nevada-licensed provider occupy a different regulatory space and have continued to operate.

Patients should ask any compounding pharmacy they consider whether they are a 503A or 503B facility. Ask to see the pharmacy's Nevada Board of Pharmacy license number and their USP 797 compliance documentation. The cost of compounded dulaglutide from a 503A pharmacy in Nevada varies widely, from as low as $0 (in patient assistance contexts) to $150 to $300 per month depending on dose and pharmacy overhead. Some Nevada telehealth providers bundle the compounded medication cost into a monthly membership fee. FDA guidance on the distinctions between 503A and 503B compounding is available at FDA.gov.

HealthRX 503A Vetting Framework for Nevada Patients

Before filling a compounded dulaglutide prescription at a Nevada 503A pharmacy, confirm all four of the following:

1. The pharmacy holds an active Nevada Board of Pharmacy license (verify at pharmacy.nv.gov).
2. The pharmacy provides a Certificate of Analysis (CoA) from an independent, ISO-accredited lab for each lot.
3. Your prescription was written by a Nevada-licensed provider who reviewed your medical history, not auto-generated from a questionnaire alone.
4. The pharmacy's compounded product is prepared as a sterile injectable under USP 797 standards, not adapted from an oral or non-sterile formulation.

Pharmacies unable to produce documentation for any of these four points should not be used for compounded injectable peptides.

Can I Get a Trulicity Prescription via Telehealth in Nevada?

Yes. Nevada law allows telehealth prescribing of controlled and non-controlled medications, and dulaglutide is a non-controlled Schedule V-or-below substance. Nevada's telehealth statutes (NRS Chapter 629) permit synchronous audio-video visits as equivalent to in-person encounters for most prescribing purposes. A Nevada-licensed physician, APRN, or PA can assess you via video, review labs electronically, and send a prescription to any Nevada-licensed pharmacy.

Practically speaking, telehealth platforms that prescribe GLP-1 medications in Nevada typically require a baseline HbA1c, fasting glucose, and a recent lipid panel before issuing a Trulicity prescription. Some platforms also request a BMI measurement and blood pressure reading obtained at a local urgent care or primary care office. The American Association of Clinical Endocrinology (AACE) Comprehensive Diabetes Management algorithm, updated in 2023, recommends individualized GLP-1 selection based on cardiovascular risk profile, HbA1c target, and tolerability considerations, all of which a telehealth provider can address remotely. The AACE 2023 guidelines are available through the AACE website.

One Nevada-specific note: if a telehealth platform is prescribing compounded dulaglutide (rather than brand Trulicity), the prescribing provider must still be Nevada-licensed and the compound must be dispensed from a Nevada-compliant pharmacy. Out-of-state pharmacies shipping compounded injectables into Nevada without a Nevada pharmacy license are operating outside state law.

What Are the Cheapest Ways to Get Trulicity in Nevada?

Cost reduction paths stack differently depending on your insurance status. Here is a ranked list by typical monthly out-of-pocket, starting with the lowest cost option.

Option 1: Lilly Cares patient assistance (uninsured, income-eligible). Cost: $0. Timeline: 3 to 6 weeks for enrollment and first shipment. Best for: uninsured Nevada residents at or below 400% FPL.

Option 2: Lilly Savings Card (commercially insured). Cost: $25 per fill. Requires: active commercial insurance that covers Trulicity at any level. Best for: employer-plan members whose deductible has not been met.

Option 3: VA formulary (eligible veterans). Cost: $0 to $15 per month. Requires: VA enrollment and a diabetes diagnosis documented in the VA record. Best for: Nevada veterans using VA facilities in Las Vegas or Reno.

Option 4: Compounded dulaglutide via 503A pharmacy. Cost: $150 to $300 per month, or bundled into a telehealth membership. Requires: prescription from a licensed Nevada provider and a vetted 503A pharmacy. Best for: uninsured patients who do not qualify for patient assistance income thresholds or who need a faster turnaround than Lilly Cares provides.

Option 5: GoodRx or Mark Cuban's Cost Plus Drugs. Trulicity is not currently listed on Cost Plus Drugs because no generic exists. GoodRx brings cash price to approximately $850 to $920 at select Nevada pharmacies. Best for: patients waiting for Lilly Cares enrollment to finalize.

Option 6: ACA marketplace plan with GLP-1 coverage. Cost varies by plan (co-pay $60 to $200 per month after deductible). Nevada Health Link open enrollment runs November 1 through January 15 each year. A plan with Trulicity on formulary and a low deductible can yield total annual costs well below the $11,172 cash-pay annual price. The CMS guidance on Part D drug pricing rules is available at CMS.gov.

How Does Trulicity Dosing Affect Monthly Cost in Nevada?

Trulicity is dispensed as a four-pen (four-week) box regardless of dose. This means the retail cash price of $931 applies whether your prescription is for 0.75 mg or 4.5 mg. Dose escalation does not increase the per-pen price at retail, though some telehealth platforms that bundle the medication charge tiered membership rates based on dose level.

The standard initiation dose is 0.75 mg once weekly for at least four weeks before considering escalation to 1.5 mg. The FDA-approved label allows titration up to 4.5 mg weekly for additional glycemic control, with each 1.5 mg step separated by at least four weeks. Gastrointestinal side effects (nausea, diarrhea, vomiting) are the primary reason patients stay at a lower dose, and they appear to be dose-dependent based on the clinical trial data submitted to the FDA.

From a budget standpoint, a patient titrating from 0.75 mg to 1.5 mg at week five does not face a price increase at retail. The same box is dispensed; the dose per injection changes. This differs from some GLP-1 compounds where higher doses are priced higher due to concentration and formulation costs.

Prior Authorization Strategy for Nevada Insurers

Prior authorization (PA) is the main barrier between a Nevada patient and covered Trulicity. Commercial insurers in Nevada typically require the following to approve a PA:

• Confirmed type 2 diabetes diagnosis (ICD-10: E11.x)
• HbA1c of 7.0% or above despite at least 90 days on metformin (or documented metformin intolerance)
• Documentation of cardiovascular disease, chronic kidney disease, or high cardiovascular risk (to justify GLP-1 over a sulfonylurea)
• Recent labs (within 6 months)

A PA supported by REWIND trial data and the ADA 2024 Standards of Care quote cited earlier stands a stronger chance of approval than one citing only glycemic need. The ADA language about cardiovascular benefit is direct and quoted from a guideline document, which carries weight with pharmacy benefit managers. The full ADA 2024 Standards of Care are indexed on the American Diabetes Association's journal platform.

If a PA is denied, Nevada law (NRS 695G) requires commercial insurers to offer an internal appeal process, and an expedited appeal must be resolved within 72 hours for urgent care situations. Patients with established cardiovascular disease on insulin who need better glycemic control may qualify for the expedited track.

Trulicity vs. Compounded Dulaglutide: What Nevada Patients Should Know Before Choosing

The core difference is regulatory standing. Brand Trulicity is FDA-approved, manufactured under GMP conditions at Eli Lilly's facilities, and each pen contains a verified dose of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg per 0.5 mL. Compounded dulaglutide from a 503A pharmacy is prepared on-site or at a central 503A facility, is not FDA-reviewed for the specific batch, and quality depends entirely on the pharmacy's internal standards and any third-party CoA testing.

That does not automatically mean compounded dulaglutide is unsafe. Many 503A pharmacies producing sterile injectables maintain rigorous quality systems. The problem is that patients cannot easily distinguish a compliant 503A pharmacy from a non-compliant one without asking the right questions, which is why the four-point vetting framework above matters.

The clinical data supporting dulaglutide's efficacy (including REWIND) was generated using the brand product. Whether compounded dulaglutide achieves identical pharmacokinetics depends on the excipients, pH, and concentration used, none of which have been independently validated in head-to-head trials against the brand. A 2024 FDA communication warned that some compounded GLP-1 products tested by the agency showed significant potency variances. That FDA safety communication is available at FDA.gov.

For a Nevada patient whose primary goal is cost reduction and who cannot access the brand through any assistance pathway, compounded dulaglutide from a vetted 503A pharmacy represents a pragmatic option, not a risk-free one.